Main > > >MELANOMA (SKIN). *

---

Adjuvant TREAT.: PembrolizuMAb Inj.
[Involvement of Lymph Node(s) Following Complete Resection (Resected Stage III)]
EU Approval Date : 2018. 12.17.
JP Approval Date : 2019. 01.03.
USA Approval Date: 2019. 02.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.20.




Diagnostics: Electrical Impedance Spec-troscopy (EIS) Device.
3G EU CE Mark Date: 2018 End
3G USA Approval Date: 2020. 05.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.26.




Diagnostics: LED Spectrophotometer.
Approved in AU, BR, CA, EU; NZ & USA.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.18.




Diagnostics: Pigmented Lesion Assay.
CA Approval Date: 2018. 01.04.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 12.16.




Prognostics: Metastasis. Recurrence.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.10.




TREAT.: AldesLeukin for Inj.
(METASTATIC)
USA Approval Year: 1998.
(*) Company : Clinigen Group Ltd.
(*) Patent : Expired.
TradeMark: ProLeukin
Web-Site : www.proleukin.com
UpDate: 2019. 02.14.




TREAT.: AterolizuMAb+Cobimetinib+Vemura-
fenib Inj. for IV Use.
(METASTATIC>BRAF+)
USA Approval Date: 2020. 07.30.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2020. 09.24.




TREAT.: Binimetinib Tablets+Encorafenib
Capsules.
(METASTATIC; BRAF+)
EU Approval Date : 2018. 09.20.
USA Approval Date: 2018. 06.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.17.




TREAT.: Cobimetinib Tablets+Vemurafenib
Tablets.
(METASTATIC; BRAF+).
BRAF V600E or V600K Mutation.
UnResectable.
AU; BR & CH Approval Date: ?
CA Approval Date : 2016. 02.25.
EU Approval Date : 2015. 11.25.
USA Approval Date: 2015. 11.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.17.




TREAT.: Dabrafenib Capsules+Trametinib
Tablets.
(METASTATIC BRAF+ or BRAF+ Melanoma In-volving Lymph Nodes After Surgery).
AU; CA; EU Approval
USA Approval Date: 2015. 11.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.02.




TREAT.: IpilimuMAb. Inj. IV Use.
(METASTATIC; UnResectable).
Anti-CTLA-4 MAb.
EU Approval Date : 2011. 07.12.>
>late-stage melanoma that has spread or
cannot be removed by surgery.
USA Approval Date: 2011. 03.>
>late-stage melanoma that has spread or
cannot be removed by surgery.
USA Approval Date: 2015. 10.28.>
>stage 3 patients as adjuvant therapy.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.16.




TREAT.: NivoluMAb Inj. for IV Use.
(METASTATIC).
PD-1 Checkpoint Inhibitor.
EU 2nd Approval Date : 2018. 07.31.>
USA 1st Approval Date: 2014. 12.22.
USA 2nd Approval Date: 2017. 12.20.>
>Company Receives FDA Approval for
NivoluMAb as Adjuvant Therapy in
Patients with Completely Resected
Melanoma with Lymph Node Involvement or
Metastatic Disease.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.17.




TREAT.: NivoluMAb+IpilimuMAb Inj. for
IV Use. (METASTATIC)
CA Approval Date : 2016. 10.31.
EU Approval Date : 2016. 05.11.
USA Approval Date: 2015. 10.01.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 10.17.




TREAT.: PembrolizuMAb Inj.
(METASTATIC; UnResectable).
EU Approval Date : 2015. 07.22.
USA Approval Date: 2015. 12.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.16.




TREAT.: Vemurafenib Tablets.
(METASTATIC; BRAF+)
BRAF Gene V600E/K Mutation(+)
EU Approval Date : 2012. 02.
USA Approval Date: 2011. 08.17.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.17.


>MELANOMA (SKIN). *'s products
This section has no products